NasdaqCM - Delayed Quote
USD
Catalyst Pharmaceuticals, Inc. (CPRX)
28.94
+0.20
(+0.70%)
At close: May 4 at 4:00:01 PM EDT
28.14
-0.80
(-2.77%)
Pre-Market: 4:21:23 AM EDT
Trade CPRX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for CPRX
- Previous Close
28.74 - Open
28.95 - Bid 28.70 x 1900
- Ask 29.01 x 1900
- Day's Range
28.45 - 29.30 - 52 Week Range
19.05 - 32.56 - Volume
948,433 - Avg. Volume
1,455,505 - Market Cap (intraday)
3.541B - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
17.23 - EPS (TTM)
1.68 - Earnings Date May 11, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.14
Recent News: CPRX
View More
Performance Overview: CPRX
Trailing total returns as of 5/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
CPRX
23.99%
S&P 500 (^GSPC)
5.19%
1-Year Return
CPRX
16.51%
S&P 500 (^GSPC)
26.63%
3-Year Return
CPRX
73.71%
S&P 500 (^GSPC)
77.31%
5-Year Return
CPRX
523.71%
S&P 500 (^GSPC)
72.90%
Earnings Trends: CPRX
View MoreAnalyst Insights: CPRX
View MoreStatistics: CPRX
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
3.51B
-
Enterprise Value
2.80B
-
Trailing P/E
17.11
-
Forward P/E
11.82
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
6.21
-
Price/Book (mrq)
3.68
-
Enterprise Value/Revenue
4.76
-
Enterprise Value/EBITDA
9.48
Financial Highlights
Profitability and Income Statement
-
Profit Margin
36.39%
-
Return on Assets (ttm)
16.48%
-
Return on Equity (ttm)
25.49%
-
Revenue (ttm)
588.99M
-
Net Income Avi to Common (ttm)
214.33M
-
Diluted EPS (ttm)
1.68
Balance Sheet and Cash Flow
-
Total Cash (mrq)
709.17M
-
Total Debt/Equity (mrq)
0.29%
-
Levered Free Cash Flow (ttm)
171.34M
Compare To: CPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: CPRX
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: CPRX
View More-
Raising target price to $32.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $32.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target -
Lowering target price to $28.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $28.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target -
Raising target price to $29.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $29.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target -
What does Argus have to say about CPRX?
CATALYST PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $27.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target
